Intellia Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
NTLA$11.17-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| INTELLIA THERAPEUTICS, INC. | |||
|---|---|---|---|
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||
| (Amounts in thousands except per share data) | |||
| Year Ended December 31, | |||
| 2025 | 2024 | 2023 | |
| Collaboration revenue | $67,671 | $57,877 | $36,275 |
| Operating expenses: | |||
| Research and development | 388,861 | 466,311 | 435,069 |
| General and administrative | 119,800 | 125,829 | 116,497 |
| Total operating expenses | 508,661 | 592,140 | 551,566 |
| Operating loss | (440,990) | (534,263) | (515,291) |
| Other income, net: | |||
| Interest income | 29,195 | 47,807 | 49,832 |
| Change in fair value of investments, net | (899) | (32,565) | - |
| Loss from equity method investment | - | - | (15,633) |
| Change in fair value of contingent consideration | - | - | (100) |
| Total other income, net | 28,296 | 15,242 | 34,099 |
| Net loss | $(412,694) | $(519,021) | $(481,192) |
| Net loss per share, basic and diluted | $(3.81) | $(5.25) | $(5.42) |
| Weighted average shares outstanding, basic and diluted | 108,376 | 98,849 | 88,770 |
| Other comprehensive income (loss): | |||
| Unrealized gain on marketable securities | 427 | 731 | 3,635 |
| Other comprehensive gain from equity method investment | - | - | 1,568 |
| Comprehensive loss | $(412,267) | $(518,290) | $(475,989) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.